

Annex 1: Recommended Indicators

PROPOSED GOAL-LEVEL INDICATORS & TARGETS¹

GOAL	TARGET BY 2015	TARGET BY 2020
Achieve a world free of poliomyelitis	Interrupt wild poliovirus transmission globally (by 2014)	Certification of poliomyelitis eradication (by 2018)
Meet global and regional elimination targets	Neonatal tetanus eliminated in all WHO regions Measles eliminated in at least four WHO regions Rubella/congenital rubella syndrome eliminated in at least two WHO regions	Measles and rubella eliminated in at least five WHO regions
Meet vaccination coverage targets in every region, country and community	Reach 90% national coverage and 80% in every district or equivalent administrative unit with three doses of diphtheria-tetanus-pertussis-containing vaccines	Reach 90% national coverage and 80% in every district or equivalent administrative unit with all vaccines in national programmes, unless otherwise recommended
Develop and introduce new and improved vaccines and technologies	At least 90 low-income and middle-income countries have introduced one or more new or underutilized vaccines	All low-income and middle-income countries have introduced one or more new or underutilized vaccines Licensure and launch of vaccine or vaccines against one or more major currently non-vaccine preventable diseases Licensure and launch of at least one platform delivery technology
Exceed the Millennium Development Goal 4 target for reducing child mortality	Reduce by two thirds, between 1990 and 2015, the under-five mortality rate (Target 4.A)	Exceed the Millennium Development Goal 4 Target 4.A for reducing child mortality

¹ These proposed indicators will be presented to the WHO EB and World Health Assembly for final review in 2013. The Strategic Advisory Group of Experts on immunization will also consider the development and addition of indicators to monitor equity in access to vaccines between countries, and integration of immunization systems into broader health systems, respectively.



PROPOSED STRATEGIC OBJECTIVE-LEVEL INDICATORS



² Provisional indicator to be finalized based on outcomes of pilot assessment in selected regions

³ The report on progress will also include a narrative report on progress with vaccine supply, pricing and procurement.